ASCLF - Week In Review: Qiming Launches $500 Million Fund For Listed Healthcare Companies
- China-based venture capital firm Qiming has raised more than $500 million to invest in shares of listed healthcare companies. The Springhill Fund, as it is called, will have an initial regional focus on Greater China and Asia.
- Shanghai Junshi Bio formed an mRNA Joint Venture with Hangzhou's Immorna to develop new drugs for cancer, plus infectious and rare diseases. Initially, the JV will have a value of $16 million, with Junshi contributing half of that in cash and Immora adding in its mRNA IP for the other half.
- Eluminex Biosciences (Suzhou), an ophthalmology biotech, in-licensed global rights to a biosynthetic cornea developed by FibroGen.
- JuventasCell Therapy of Beijing closed a Series C financing of over $62 million todevelop its lead CAR-T candidate, stem cell (iPSCs) technology and gene editingplatform.
For further details see:
Week In Review: Qiming Launches $500 Million Fund For Listed Healthcare Companies